← feed

Is NCT03246685 results overdue?

Yes — results are overdue. Primary completion was 2018-04-13; the FDAAA-801 reporting deadline (2019-04-13) passed 2672 days ago and no results are posted on ClinicalTrials.gov.

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

NCT IDNCT03246685 ↗
SponsorHiberCell, Inc. (INDUSTRY)
PhasePHASE2
StatusTERMINATED
Primary completion2018-04-13 (ACTUAL)
Reporting deadline2019-04-13 (completion + 365d)
Days overdue2672
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 ab2edbb7b755993a… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03246685. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →